Stock Price Forecast

March 14, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Denali Therapeutics Inc chart...

About the Company

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

$330M

Total Revenue

433

Employees

$3B

Market Capitalization

-20.82

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $DNLI News

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

19d ago, source: Hosted on MSN

Denali Therapeutics DNLI incurred a loss of 86 cents ... A better-ranked stock from the drug/biotech industry is Puma Biotechnology, Inc. PBYI, sporting a Zacks Rank #1 (Strong Buy) at present.

4 Analysts Assess Denali Therapeutics: What You Need To Know

19d ago, source: Business Insider

Unveiling the Story Behind Denali Therapeutics Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease.

Denali Therapeutics Announces $500 million Private Placement Equity Financing

20d ago, source: Business Insider

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

21d ago, source: Stockhouse

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...

Denali Therapeutics Inc DNLI

25d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Denali Therapeutics Inc (4DN.SG)

28d ago, source: Yahoo Finance

Drug developer Denali Therapeutics said on Friday its and partner Sanofi's experimental drug for a fatal neurodegenerative disease failed to slow decline of motor function in a mid-stage study.

Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results

21d ago, source: Yahoo Finance

Warning! GuruFocus has detected 2 Warning Sign with DNLI. Denali Therapeutics Inc (NASDAQ:DNLI) released its 8-K filing on February 27, 2024, detailing its financial results for the fourth quarter ...

Denali Therapeutics Announces $500 million Private Placement Equity Financing

21d ago, source: Stockhouse

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...

4 Analysts Assess Denali Therapeutics: What You Need To Know

19d ago, source: Benzinga.com

Stay informed and make data-driven decisions with our Ratings Table. Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat ...

Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

20d ago, source: Finanznachrichten

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...